Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Amado RG; Wolf M; Peeters M; Van Cutsem E; Siena S; Freeman DJ; Juan T; Sikorski R; Suggs S; Radinsky R; Patterson SD; Chang DD; Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology, 2008, vol. 26, issue 10, p 1626, ISSN 15277755. ISBN 15277755.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef